Howell, MD, PhD The good, bad, and ugly of direct-to-consumer advertising by Sheldon Sloan, MD, David A
Washington, DC, USA: 1998
Overall, the available clinical evidence suggests that GLP-1RAs may confer modest protection against nonfatal ischaemic stroke in patients with type 2 diabetes, although effect estimates are not uniform across individual trials and frequently reflect limited power for stroke-specific endpoints
doi: 10.3389/fnut.2020.598286 Received 24 August 2020 Accepted 13 October 2020 Published 04 December 2020 Volume 7 - 2020 Edited by Eduardo Dellacassa, Universidad de la Repblica, Uruguay Reviewed by Otniel Freitas-Silva, Embrapa Food Agroindustry, Brazil
Some patients find that alcohol affects them differently while taking a GLP-1 medication, especially if they are eating less than usual
V.MadsenJ